Solares S, Leon J, Garcia-Gutierrez L
Cancers (Basel). 2025; 16(24.
PMID: 39766110
PMC: 11674381.
DOI: 10.3390/cancers16244212.
Arthur N, Christensen K, Mannino K, Ruzinova M, Kumar A, Gruszczynska A
Clin Cancer Res. 2024; 30(16):3622-3639.
PMID: 38848040
PMC: 11326984.
DOI: 10.1158/1078-0432.CCR-24-0926.
Alderman C, Anderson R, Zhang L, Hughes C, Li X, Ebmeier C
J Biol Chem. 2024; 300(7):107408.
PMID: 38796066
PMC: 11328874.
DOI: 10.1016/j.jbc.2024.107408.
Freie B, Carroll P, Varnum-Finney B, Ramsey E, Ramani V, Bernstein I
Genes Dev. 2024; 38(5-6):253-272.
PMID: 38565249
PMC: 11065175.
DOI: 10.1101/gad.351292.123.
Molina E, Garcia-Gutierrez L, Junco V, Perez-Olivares M, de Yebenes V, Blanco R
Oncogene. 2023; 42(45):3358-3370.
PMID: 37773203
DOI: 10.1038/s41388-023-02846-9.
Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.
Vizkeleti L, Spisak S
Cells. 2023; 12(13).
PMID: 37443779
PMC: 10341379.
DOI: 10.3390/cells12131745.
Deep learning for MYC binding site recognition.
Fioresi R, Demurtas P, Perini G
Front Bioinform. 2022; 2:1015993.
PMID: 36544623
PMC: 9760990.
DOI: 10.3389/fbinf.2022.1015993.
Targeting Transcription Factors in Cancer: From "Undruggable" to "Druggable".
Tao Z, Wu X
Methods Mol Biol. 2022; 2594:107-131.
PMID: 36264492
PMC: 9724592.
DOI: 10.1007/978-1-0716-2815-7_9.
Cancer-driving mutations are enriched in genic regions intolerant to germline variation.
Vitsios D, Dhindsa R, Matelska D, Mitchell J, Zou X, Armenia J
Sci Adv. 2022; 8(34):eabo6371.
PMID: 36026442
PMC: 9417173.
DOI: 10.1126/sciadv.abo6371.
Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor.
Welcker M, Wang B, Rusnac D, Hussaini Y, Swanger J, Zheng N
Sci Adv. 2022; 8(4):eabl7872.
PMID: 35089787
PMC: 8797792.
DOI: 10.1126/sciadv.abl7872.
Luminescence complementation technology for the identification of MYC:TRRAP inhibitors.
Feris E, Hinds J, Cole M
Oncotarget. 2021; 12(21):2147-2157.
PMID: 34676047
PMC: 8522838.
DOI: 10.18632/oncotarget.28078.
Gene Transactivation and Transrepression in MYC-Driven Cancers.
Scafuro M, Capasso L, Carafa V, Altucci L, Nebbioso A
Int J Mol Sci. 2021; 22(7).
PMID: 33801599
PMC: 8037706.
DOI: 10.3390/ijms22073458.
The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.
Guerra B, Recio C, Aranda-Tavio H, Guerra-Rodriguez M, Garcia-Castellano J, Fernandez-Perez L
Front Oncol. 2021; 11:626971.
PMID: 33718197
PMC: 7947625.
DOI: 10.3389/fonc.2021.626971.
MYC dysfunction modulates stemness and tumorigenesis in breast cancer.
Liu Y, Zhu C, Tang L, Chen Q, Guan N, Xu K
Int J Biol Sci. 2021; 17(1):178-187.
PMID: 33390842
PMC: 7757029.
DOI: 10.7150/ijbs.51458.
Emerging roles of DYRK2 in cancer.
Tandon V, de la Vega L, Banerjee S
J Biol Chem. 2020; 296:100233.
PMID: 33376136
PMC: 7948649.
DOI: 10.1074/jbc.REV120.015217.
MYC Activity Inference Captures Diverse Mechanisms of Aberrant MYC Pathway Activation in Human Cancers.
Schaafsma E, Zhao Y, Zhang L, Li Y, Cheng C
Mol Cancer Res. 2020; 19(3):414-428.
PMID: 33234576
PMC: 7925347.
DOI: 10.1158/1541-7786.MCR-20-0526.
Peroxynitrite promotes serine-62 phosphorylation-dependent stabilization of the oncoprotein c-Myc.
Raman D, Chong S, Iskandar K, Hirpara J, Pervaiz S
Redox Biol. 2020; 34:101587.
PMID: 32512497
PMC: 7280771.
DOI: 10.1016/j.redox.2020.101587.
The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.
Mudgapalli N, Nallasamy P, Chava H, Chava S, Pathania A, Gunda V
Mol Aspects Med. 2019; 70:21-32.
PMID: 31623866
PMC: 7775410.
DOI: 10.1016/j.mam.2019.10.001.
Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression.
Yang P, Jiang Y, Pan Y, Ding X, Rhea P, Ding J
Sci Rep. 2019; 9(1):6428.
PMID: 31015523
PMC: 6478697.
DOI: 10.1038/s41598-019-41444-2.
Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer.
Maik-Rachline G, Hacohen-Lev-Ran A, Seger R
Int J Mol Sci. 2019; 20(5).
PMID: 30857244
PMC: 6429060.
DOI: 10.3390/ijms20051194.